Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

September 20, 2018

Conditions
Prostatic Neoplasm
Interventions
DRUG

Perflutren Lipid Microsphere Intravenous Suspension

The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.

Trial Locations (1)

19107

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Thomas Jefferson University

OTHER

NCT02967458 - Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study | Biotech Hunter | Biotech Hunter